You are here

New Fluticasone Furoate/Vilanterol Combo Drug Submitted for FDA Review

GSK and Theravance seek an indication for FF/VI (100/25 mcg) for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

GSK and Theravance are reviewing the strategy for a future U.S. filing for asthma.

FF/VI is one of several respiratory medicines being developed by GSK. Other potential products include the investigational LAMA/LABA combination umeclidinium bromide (UMEC)/VI, VI monotherapy, and MABA (GSK961081), all developed in collaboration with Theravance. GSK is also developing FF monotherapy, UMEC monotherapy, and an anti-IL5 monoclonal antibody (mepolizumab).

Read the news release from GlaxoSmithKline.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile